The Bayh-Dole Act has driven U.S. innovation by enabling public-private partnerships that fuel economic growth and life-saving discoveries. The White House proposal to expand “march-in rights” for price controls could discourage private investment, slow scientific progress, and jeopardize future breakthroughs in medicine and technology. According to Hawks Bland, “expanding march-in rights would have a particularly negative impact on the bioscience industry, which has seen over 200 treatments and vaccines developed under Bayh-Dole.”